Adamas Pharmaceuticals Inc (ADMS) Stock News
NASDAQ:ADMS - Nasdaq - Common Stock
ADMS Latest News, Press Relases and Analysis
Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS
/PRNewswire/ -- Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of California has approved the following...
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021
Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:
East Bay drug maker's potential sale brings lawsuits, job cuts
Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For a few dollars more: Behind the half-billion-dollar deal for an East Bay Parkinson's Disease drug company
Mentions: SUPN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Columbia Banking System, Inc. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of Columbia
Why Supernus' Acquisition of Adamas Is a Smart Move
Adamas looks like a good fit for Supernus.
Mentions: SUPN
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Adamas Pharmaceuticals, Inc.
/PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas...
Mentions: SUPN
East Bay Parkinson's drug maker to be swallowed up in potential $450M deal
Supernus Pharmaceuticals to acquire this Pharmaceuticals company for $400 million
Merck is seeking the FDA's permission for emergency use of its experimental antiviral drug in treating COVID-19.
Mentions: SUPN
Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus
/PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with...
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million.
Mentions: SUPN
Adamas Announces New Employment Inducement Grants
Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards
Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress
